These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38287743)

  • 1. Genetic testing for familial melanoma.
    Primiero CA; Maas EJ; Wallingford CK; Soyer HP; McInerney-Leo AM
    Ital J Dermatol Venerol; 2024 Feb; 159(1):34-42. PubMed ID: 38287743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [From gene to disease; from p16 to melanoma].
    Gruis NA; Bergman W
    Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.
    Delaunay J; Martin L; Bressac-de Paillerets B; Duru G; Ingster O; Thomas L
    JAMA Dermatol; 2017 Nov; 153(11):1122-1129. PubMed ID: 28903138
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
    Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
    [No Abstract]   [Full Text] [Related]  

  • 5. [Increased knowledge on familial melanoma and the underlying genetics].
    Helgadottir H; Nielsen K; Höiom V
    Lakartidningen; 2017 May; 114():. PubMed ID: 28485764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genetic counseling and DNA testing in patients with increased risks for malignant melanoma].
    Itin PH; Fistarol SK
    Ther Umsch; 2003 Aug; 60(8):469-72. PubMed ID: 14502854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis.
    Taibo A; Paradela S; Suanzes-Hernández J; Balboa-Barreiro V; Amado-Bouza J; Fonseca E
    Melanoma Res; 2024 Feb; 34(1):9-15. PubMed ID: 37924530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial melanoma: a complex disorder leading to controversy on DNA testing.
    de Snoo FA; Bergman W; Gruis NA
    Fam Cancer; 2003; 2(2):109-16. PubMed ID: 14574160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a role for genetic testing in patients with melanoma?
    Kefford RF; Mann GJ
    Curr Opin Oncol; 2003 Mar; 15(2):157-61. PubMed ID: 12601281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.
    Mantelli M; Pastorino L; Ghiorzo P; Barile M; Bruno W; Gargiulo S; Sormani MP; Gliori S; Vecchio S; Ciotti P; Sertoli MR; Queirolo P; Goldstein AM; Bianchi-Scarrà G;
    Melanoma Res; 2004 Dec; 14(6):443-8. PubMed ID: 15577313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geographical variation in the penetrance of CDKN2A mutations for melanoma.
    Bishop DT; Demenais F; Goldstein AM; Bergman W; Bishop JN; Bressac-de Paillerets B; Chompret A; Ghiorzo P; Gruis N; Hansson J; Harland M; Hayward N; Holland EA; Mann GJ; Mantelli M; Nancarrow D; Platz A; Tucker MA;
    J Natl Cancer Inst; 2002 Jun; 94(12):894-903. PubMed ID: 12072543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
    J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parental preferences for CDKN2A/p16 testing of minors.
    Taber JM; Aspinwall LG; Kohlmann W; Dow R; Leachman SA
    Genet Med; 2010 Dec; 12(12):823-38. PubMed ID: 21045708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The genetics of hereditary melanoma and nevi. 1998 update.
    Greene MH
    Cancer; 1999 Dec; 86(11 Suppl):2464-77. PubMed ID: 10630172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
    Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
    J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of familial melanoma.
    Bishop JN; Harland M; Randerson-Moor J; Bishop DT
    Lancet Oncol; 2007 Jan; 8(1):46-54. PubMed ID: 17196510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
    Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
    Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).
    Vasen HF; Gruis NA; Frants RR; van Der Velden PA; Hille ET; Bergman W
    Int J Cancer; 2000 Sep; 87(6):809-11. PubMed ID: 10956390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene.
    Puig S; Ruiz A; Castel T; Volpini V; Malvehy J; Cardellach F; Lynch M; Mascaro JM; Estivill X
    Hum Genet; 1997 Dec; 101(3):359-64. PubMed ID: 9439668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Potential Melanoma Predisposition Genes in High-Risk Brazilian Patients.
    Soares de Sá BC; Moredo LF; Torrezan GT; Fidalgo F; de Araújo ÉSS; Formiga MN; Duprat JP; Carraro DM
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.